ArticleScientific reports2025
The mechanism of luteolin suppressing pancreatic cancer (PC) via cyclin B1 (CCNB1)-mediated signalling.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Pancreatic cancer is a highly aggressive malignancy with a poor prognosis, often diagnosed at advanced stages. Current treatments are limited, underscoring the need for effective therapies. Recent studies suggest that luteolin exhibits significant anti-tumor activity, yet its mechanisms in pancreatic cancer remain poorly understood. This study explored the anti-tumor mechanism of luteolin in pancreatic cancer (PC), focusing on its regulation of cyclin B1 (CCNB1)-mediated cell cycle progression. PANC-1 and SW1990 cell lines were used for assays of cell proliferation, migration, and invasion, and flow cytometry was used to assess cell cycle distribution and apoptosis. The efficacy of luteolin was further evaluated in patient-derived organoids (PDOs) and a mouse xenograft model. To identify molecular targets, we employed network pharmacology and transcriptomic sequencing, followed by experimental validation using Western blot, molecular docking, and surface plasmon resonance (SPR) assays to confirm luteolin's interaction with CCNB1 and its effects on downstream signaling pathways. Luteolin exhibited a dose-dependent inhibitory effect on pancreatic cancer cell proliferation, migration, and invasion. It induced G2/M cell cycle arrest and apoptosis, with significant suppression of PDO growth. In vivo, luteolin effectively inhibited subcutaneous tumor growth in a xenograft mouse model without causing systemic toxicity or organ damage. Network pharmacology and transcriptomic analyses identified CCNB1 as a pivotal target, and experimental validation confirmed luteolin's direct binding to CCNB1. This interaction disrupted the CCNB1/cyclin-dependent kinase 1 (CDK1) complex, leading to cell cycle arrest and reduced tumor progression. Luteolin suppresses pancreatic cancer growth by targeting CCNB1-mediated cell cycle regulation, inducing G2/M arrest, and promoting apoptosis. This highlights its potential as a therapeutic agent in pancreatic cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.